SparkRx by Limbix Health, for example, is a digital therapeutic that is indicated for the treatment of adolescent depression. It is available without a prescription since the COVID-19 pandemic, under the FDA’s emergency guidance for digital health devices used in the treatment of psychiatric disorders. The COVID-19 pandemic has expedited the adoption of DTx, especially with regard to mental illness and chronic ailments like diabetes and CVS. The U.S. FDA released new guidelines for the computerized behavioral therapy and other DTx solutions during this public health emergency.
The organization has waived off guidelines that include 510(k) premarket notifications, registration & listing requirements, and Unique Device Identification (UDI) requirements for DTx therapeutic devices with low risk. For instance, Pear therapeutics launched Pear-004 for psychosis and self-management training post the introduction of the new guidelines. The product needs to be used under a doctor’s supervision.
The need for cost-effective healthcare is increasing globally due to rising healthcare expenditure. Digital health technology is being encouraged and preferred to avoid unnecessary costs and promote cheaper, alternative means of healthcare delivery, thus propelling the market. Moreover, the rising demand for remote monitoring services due to the increasing incidences of chronic diseases worldwide is one of the factors propelling the market growth. Digital therapeutic applications allow patients to manage and treat diseases without constant medical intervention, thereby drastically reducing the healthcare expenditure.
U.S. Digital Therapeutics Market Report Highlights
- The digital therapeutics market in the U.S. was valued at USD 1.5 billion in 2021 and is expected to advance at a CAGR of 24.8% during the forecast period.
- In terms of revenue, diabetes dominated the application segment in 2021. The growth can be attributed to the increasing incidence of this disease and the rising demand for self-management and constant monitoring.
- Digital therapeutics solutions find application in 3 key product categories - products to manage a condition, treat a disease, and improve a health function; as such, the demand for these solutions is expected to increase in the coming years owing to the rising burden of chronic disorders.
- On the basis of end-use, the patient segment held the largest revenue share in 2021, owing to the increased adoption of healthcare IT services through AI-driven smartphone apps.
- In the wake of the COVID-19 pandemic, patients with chronic diseases have been facing challenges in managing medications, visiting healthcare providers, and maintaining a balanced diet. DTx therapy can be useful in managing patient conditions remotely.
- In January 2020, Pear Therapeutics and Crossroads Treatment Centers entered into a partnership to incorporate reSET-O PDT in several opioid use disorder treatment centers located in Pennsylvania, thereby enhancing its market reach.
This product will be delivered within 1-3 business days.
What is the estimated value of the U.S. Digital Therapeutics Market?
What is the growth rate of the U.S. Digital Therapeutics Market?
What is the forecasted size of the U.S. Digital Therapeutics Market?
Who are the key companies in the U.S. Digital Therapeutics Market?
|No. of Pages||130|
|Forecast Period||2022 - 2030|
| Estimated Market Value ( USD ||$ 1.8 Billion|
| Forecasted Market Value ( USD ||$ 10.5 Billion|
|Compound Annual Growth Rate||24.8%|
|Regions Covered||United States|
|No. of Companies Mentioned||12|
Table of Contents
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.7 List Of Secondary Sources
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2. Penetration & Growth Prospect Mapping, 2021
3.3 U.S. Digital Therapeutics Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.3.3. Market Opportunity Analysis
3.3.4. Market Challenge Analysis
3.4 U.S. Digital Therapeutics Market Analysis Tools: Porter’s Five Forces
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Substitution Threat
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 U.S. Digital Therapeutics Industry Analysis-Pest (Political & Legal, Economic, Social, And Technological)
3.5.1 Political/Legal Landscape
3.5.2 Economic Landscape
3.5.3 Social Landscape
3.5.4 Technology Landscape
3.6. Regulatory & Reimbursement Scenario
4.2. Current Impact & Future Scenario
4.3. Impact On Market Players
5.2 U.S. Digital Therapeutics Market, By Application, 2017 To 2030
5.3.1 Diabetes Market, 2017-2030 (USD Million)
5.4.1 Obesity Market, 2017-2030 (USD Million)
5.5.1 CVD Market, 2017-2030 (USD Million)
5.6 Respiratory Diseases
5.6.1 Respiratory Diseases Market, 2017-2030 (USD Million)
5.7 Smoking Cessation
5.7.1 Smoking Cessation Market, 2017-2030 (USD Million)
5.8 CNS Disease
5.8.1 CNS Disease Market, 2017-2030 (USD Million)
5.9.1 Others Market, 2017-2030 (USD Million)
6.2 U.S. Digital Therapeutics Market, By End Use, 2017 To 2030
6.3.1 Patients Market, 2017-2030 (USD Million)
6.4.1 Providers Market, 2017-2030 (USD Million)
6.5.1 Payers Market, 2017-2030 (USD Million)
6.6.1 Employers Market, 2017-2030 (USD Million)
6.6.1 Others Market, 2017-2030 (USD Million)
7.1.1. Company Market Position Analysis
7.1.2. Synergy Analysis: Major Deals & Strategic Alliances
7.1.3. Market Leaders & Innovators
7.2. List Of Key Companies
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 End Use Benchmarking
8.1.4 Strategic Initiatives
8.2 Teladoc Health, Inc.
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 End Use Benchmarking
8.2.4 Strategic Initiatives
8.3 2morrow Inc.
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 End Use Benchmarking
8.3.4 Strategic Initiatives
8.4 Propeller Health (Resmed)
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 End Use Benchmarking
8.4.4 Strategic Initiatives
8.5 Fitbit Health Solutions
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 End Use Benchmarking
8.5.4 Strategic Initiatives
8.6 Canary Health
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 End Use Benchmarking
8.6.4 Strategic Initiatives
8.7 Welldoc, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 End Use Benchmarking
8.7.4 Strategic Initiatives
8.8 Noom, Inc.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 End Use Benchmarking
8.8.4 Strategic Initiatives
8.9 Pear Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 End Use Benchmarking
8.9.4 Strategic Initiatives
8.10 Click Therapeutics, Inc.
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 End Use Benchmarking
8.10.4 Strategic Initiatives
8.11 Akili Interactive Labs, Inc.
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 End Use Benchmarking
8.11.4 Strategic Initiatives
8.12 Better Therapeutics, Inc
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 End Use Benchmarking
8.12.4 Strategic Initiatives
Table 2 List of Key companies
Table 3 U.S. Digital Therapeutics market, by End Use, 2017-2030 (USD Million)
Table 4 U.S. Digital Therapeutics market, 2017-2030 (USD Million)
Table 5 U.S. Digital Therapeutics market, by Application, 2017-2030 (USD Million)
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity workflow analysis
Fig. 9 U.S. Digital Therapeutics market snapshot, 2021 (USD Million)
Fig. 10 U.S. Digital Therapeutics market segmentation and scope
Fig. 11 Parent market outlook
Fig. 12 Ancillary market outlook
Fig. 13 Penetration & growth prospect mapping, 2021
Fig. 14 U.S. Digital Therapeutics market dynamics analysis
Fig. 15 U.S. Digital Therapeutics market driver analysis
Fig. 16 U.S. Digital Therapeutics market restraint analysis
Fig. 17 COVID-19 disease prevalence
Fig. 18 U.S. Digital Therapeutics market: End-Use movement analysis, 2021 & 2030
Fig. 19 U.S. Digital Therapeutics market End-Use outlook: Key takeaways
Fig. 20 Patients market, 2017-2030 (USD Million)
Fig. 21 Providers market, 2017-2030 (USD Million)
Fig. 22 Payers market, 2017-2030 (USD Million)
Fig. 23 Employers market, 2017-2030 (USD Million)
Fig. 24 Others market, 2017-2030 (USD Million)
Fig. 25 U.S. Digital Therapeutics market: Application movement analysis, 2021 & 2030
Fig. 26 U.S. Digital Therapeutics market Application outlook: Key takeaways
Fig. 27 Diabetes market, 2017-2030 (USD Million)
Fig. 28 Obesity market, 2017-2030 (USD Million)
Fig. 29 CVD market, 2017-2030 (USD Million)
Fig. 30 Respiratory Diseases market, 2017-2030 (USD Million)
Fig. 31 Smoking Cessation market, 2017-2030 (USD Million)
Fig. 32 CNS Disease market, 2017-2030 (USD Million)
Fig. 33 Others market, 2017-2030 (USD Million)
Fig. 34 Market participant categorization
Fig. 35 Company market position analysis
- Omada Health Inc.
- Teladoc Health, Inc.
- 2morrow Inc.
- Propeller Health (Resmed)
- Fitbit Health Solutions
- Canary Health
- Welldoc, Inc.
- Noom, Inc.
- Pear Therapeutics, Inc.
- Click Therapeutics, Inc.
- Akili Interactive Labs, Inc.
- Better Therapeutics, Inc